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pharmaceutical policy in reducing inequalities
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From 3rd International PPRI Conference 2015: Pharmaceutical Pricing and Reimbursement Policies: Challenges
Beyond the Financial Crisis
Vienna, Austria. 12-13 October 2015
Background
Even though access to essential medicines is a human
right, inequalities in access resulting in differences in med-
icine use between socioeconomic groups are known from
several countries world-wide. However, the socioeconomic
determinants of medicine use in Central and Eastern
European countries (CEECs) have not yet been explored.
For a sample of eight countries (Bulgaria, Czech Republic,
Hungary, Latvia, Poland, Romania, Slovenia, and Slovakia),
this study thus aims to analyse whether socioeconomic
status influences medicine use and investigates to what
extent observed inequalities can be explained by current
(lack of) pharmaceutical policies and how policies can
help reduce existing inequalities.
Methods
Quantitative analyses on socioeconomic determinants of
medicine use (based on cross-sectional data from the
first wave of the European Health Interview Survey) and
qualitative analyses of the national pharmaceutical policy
framework (based on information produced in the
Pharmaceutical Pricing and Reimbursement Information
project) for the time period 2006-2009 were conducted.
Results
Women and people with chronic diseases and lower self-
assessed health were found to have a higher likelihood to
take medicines. In the field of non-prescribed medicines
that were usually not reimbursed by the public payers,
people with higher education and/or higher income were
attributed a higher chance of consuming these medicines
in seven of the surveyed countries. Regarding prescribed
medicines, such a socioeconomic gradient in medicine use
was only observed in three countries (Latvia, Poland, and
Romania). The analysis of pharmaceutical policies identi-
fied private expenditure, overall investment in health sys-
tems, rational use of medicines and clear procedures for
inclusion of medicines into reimbursement as major fac-
tors that co-determine this socioeconomic gradient in
medicine use in Central and Eastern Europe. Latvia,
Poland and Romania had a comparably high share of
patients’ contributions, and Latvia and Romania were
furthermore strongly hit by the global financial crisis and
reacted through cost-containment measures.
Conclusions
A socioeconomic gradient in medicine consumption was
found in the CEECs, particularly regarding non-
prescribed medicines and, as a trend, it tended to favour
the more affluent population. Public pharmaceutical
policies usually addressed prescribed, reimbursed medi-
cines, and in several CEECs they appeared to have posi-
tively contributed to improving access to these
medicines for people with a lower socioeconomic status.
Pharmaceutical policies aiming at reducing inequalities
in medicine use require not only a consideration of the
role of co-payments and other private expenditure but
also adequate investment in medicines and transparent
and clear processes regarding the inclusion of medicines
into reimbursement.
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